Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Ku-In Kang

Physician Assistant Hagatna, GU Physician Assistant

NPI 1902267461 CMS profile 10806481

302 South Route 4, 207, Hagatna, GU 96932

Open in the dashboard

General payments

$7,331

390 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ku-In Kang of Hagatna, GU is reported in the CMS Open Payments database as having received $7,331 across 390 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,830 90
2024 General $1,900 108
2023 General $1,604 77
2022 General $1,998 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ku-In Kang
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ku-In Kang were reported at $1,830. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ku-In Kang Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $1,998 $155 $48–$522 $149
2023 $1,604 $167 $52–$557 $160
2024 $1,900 $178 $55–$600 $164
2025 $1,830 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,114 60 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $705 43 payments
  3. Amgen Inc. $630 35 payments
  4. AstraZeneca Pharmaceuticals LP $623 38 payments
  5. Novo Nordisk Inc $421 28 payments
  6. Gilead Sciences, Inc. $408 12 payments
  7. Sumitomo Pharma America, Inc. $372 19 payments
  8. Sanofi-Aventis U.S. LLC $300 15 payments
  9. Astellas Pharma US Inc $294 8 payments
  10. Scilex Pharmaceuticals Inc. $270 12 payments
  11. Other $2,194 120 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,270 389 payments
  2. Education $61 1 payment
Products named General payments · program years 2022–2025
  1. Kerendia $705 43 payments
  2. LINZESS $672 36 payments
  3. CREON $647 37 payments
  4. EVENITY $405 21 payments
  5. Ozempic $403 27 payments
  6. GEMTESA $372 19 payments
  7. ZENPEP $362 22 payments
  8. RYBELSUS $350 24 payments
  9. SOLIQUA 100/33 $300 15 payments
  10. AIRSUPRA $265 14 payments
  11. Other $4,223 227 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

390 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Guam

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record